Stocks · News reference
The German Federal Cartel Office (Bundeskartellamt) has recorded a merger control proceeding regarding the acquisition of Silence Therapeutics plc by Merck KGaA.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Moody's Investors Service confirmed Merck KGaA's 'A3' long-term credit rating, citing the company's solid operational performance and the expected impact of its planned acquisitions, including Silence Therapeutics.
Investor rights law firm Halper Sadeh LLC is investigating whether the proposed acquisition of Silence Therapeutics plc by Merck KGaA provides fair value to shareholders.
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39. The S&P 500 also